Remodeling of Tumor Microenvironment by Microwave Ablation Potentiates Immunotherapy of AXL-specific CAR-T Cells against Non-small Cell Lung Cancer

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The tumor microenvironment (TME) is a complex tissue that promotes tumor cell proliferation while suppressing T cell efficacy and exhausting them. Breaking the barrier requires regulating the TME and identifying tumor-specific antigens.

A Chinese team created a novel adoptive tumor immunotherapy for lung cancer. Researchers confirmed that AXL is highly expressed in non-small cell lung cancer (NSCLC) tumor cells but not in normal organs or tissues in this study, indicating that AXL could be a valuable candidate for CAR-T therapy for NSCLC. Scientists created CAR-T cells using the most affinity anti-AXL single-chain fragment variables (scFvs). In vivo studies revealed that AXL-specific CAR-T cells have significant anti-tumor efficacy in subcutaneous and pulmonary metastatic lung cancer cell-derived xenograft models.

Microwave ablation (MWA) is a valuable treatment option for patients with inoperable lung cancer. In cell-derived xenografts and AXL-positive NSCLC patient-derived xenografts, the combination of MWA and AXL-directed CAR-T demonstrated enhanced tumor cell-killing function. MWA reduced the extracellular matrix in TME, increased vascularisation, and decreased tumor interstitial fluid pressure, all of which improved the ability of AXL-CAR-T cells to infiltrate, accumulate, and suppress tumors. Mitochondrial oxidative metabolism analysis of tumor-infiltrating CAR-T cells revealed that hypoxia was reduced in the TME, allowing for central memory cell differentiation and maintenance.

Above all, the study found that a combination strategy had high safety and superior cytotoxicity to solid tumors, with the potential to be translated into clinical NSCLC treatment.

Fig.1 MWA promotes antitumour activity of AXL-CAR T cells against lung cancer. (Cao, 2022)

Our Services

Creative Biolabs has developed an advanced and mature CAR-T production platform based on cutting-edge technology and decades of research experience. We provide a full range of services, including biomarker identification, CAR-T generation, and preclinical assays for CAR-T efficacy assessment. Please contact us if you require any additional information.

Biomarker Identification & Selection

Biomarkers are the most important and fundamental components in developing an effective CAR-T immunotherapy. We provide the most professional and sophisticated biomarker identification and selection services at Creative Biolabs. We can create CAR-T therapy targeting over 1,000 cancer biomarkers.

Learn More

scFv Generation

scFv Generation for CAR-T

A superior scFv with high specificity and affinity results in an even better CAR-T therapy. Creative Biolabs has a world-class scientific team that specializes in antibody engineering. We provide superior scFv selection solutions to customers using the most mature and delicate technology, such as hybridoma and phage display.

Learn More

CAR Vector Products

Creative Biolabs, the leading CAR-T cell therapy biotech, has the most advanced technology and offers the best CAR vector products to clients. Four generations of CAR constructs covering more than 900 tumor-associated antigen targets are included in our vector products.

Learn More

CAR-T Preclinical

CAR-T Preclinical In Vivo Assay

Using the CellRapeutics™ platform, Creative Biolabs provides global one-stop CAR-T preclinical in vivo assay services for hematoma and multiple solid tumors. We provide services such as CAR-T viability and bio-distribution studies, efficacy tests, and toxicity evaluations using various animal models.

Learn More

Mitochondrial Oxidative Metabolism of CAR-T cells

The persistence and clinical outcome of CAR-T cell therapy are determined by mitochondrial activity. Creative Biolabs provides clients with mitochondrial dynamics analysis of CAR-T cells, including but not limited to the assessment of OCR and ECAR.

Related Products at Creative Biolabs

With decades years of experience in cell therapeutic development, Creative Biolabs offers CAR-T cell therapy development services and associated viral vectors and car-cells for complex cancer treatment studies, targeting Leukemia and various solid tumors. Extensive experiments have verified our products with accurate and reliable results. You can find the proper products below for your novel CAR-T production.

CD19-Targeted Product Category	AXL-Targeted Product Category
Anti-CD19 CAR Vector Products CD19 Stable Cell Line Anti-CD19 CAR Viral Particle Products Anti-CD19 CAR Lentivirus Packaging Kit Anti-CD19 CAR Animal Cells Anti-CD19 CAR-iT Cells Products Kits for CARs/TCRs Development Immune Cell Products	Anti-AXL CAR Animal Cells Anti-AXL CAR Vector Products Anti-AXL CAR-iT Cells Products Anti-AXL CAR-CIK Cells Products Anti-AXL Viral Particle Products Anti-AXL CAR-Jurkat Cells Products

Reference

Cao B, Liu M, Wang L, et al. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR-T cells against non-small cell lung cancer. Nat Commun. 2022;13 (1):6203.